OPGN BACK to $4 NOW, Open LONG!!! $$$$11.5 million funding on the way, retail investors with their eye on it, recently trading at 1000%.
Back to $4 in a matter of days! LETS GOOO!!
−6.5212USD
−37.28 MUSD
2.61 MUSD
9.97 M
About OpGen, Inc.
Sector
CEO
David Elliot Lazar
Website
Headquarters
Rockville
Employees (FY)
100
Founded
2001
ISIN
US68373L4068
FIGI
BBG001J1CY88
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
OPGN 1W headed to AFinally a trip to the top of the down channel. How exciting for OPGN holders yesterday as they finally felt the sting lessen. $4.43 is is the target price. Lets go!
OPGEN INC.
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat in
OPGN 1M Decline -62% to $0.07. Rebound $0.14 and then $0.01Do you wear Fleece? Its going to be cold.
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The fi
OPGN | Interesting Setup | WatchingOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bac
OPGN 15min Scalpers editiontest
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians ab
OPGN. P-Modeling Pt X-1 The Cajun WaveFunction of WonderWelcome Hyperspace Travelers.
This is going to be one of the most profitable trades I ever engage in. I wish you to join me at your own risk. I know you will doubt what I am about to say..
But that is the funny thing about my work. Your doubt is my gain.
OPGN Is going to enter a miraculous dep
OPGN Action Close Up 1Wtest
OPGEN INC.
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to cl
Zero hour The move today was solid, whether it be fomo for the possibility of a clearance decision to be made or valuation of the company starting to be realized, money will be made.
I can’t be certain on what the future holds or if the FDA will clear the acuitas lighthouse product, but I have a positive ou
OPGN A Tale Of 2 FibsOPGN has slowly crept up ever since that insider buying in June. After meandering around the 786 fib line for weeks, the stock finally headed back toward that 618 fib line and...yet again...was rejected at that level. In general, momentum has been building in the stock but now with some attention,
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of OPGN is 0.6161 USD — it has increased by 2.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange OpGen, Inc. stocks are traded under the ticker OPGN.
OpGen, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
OPGN stock is 9.04% volatile and has beta coefficient of 1.29. Check out the list of the most volatile stocks — is OpGen, Inc. there?
OPGN earnings for the last quarter are −0.93 USD whereas the estimation was −0.71 USD which accounts for −30.99% surprise. Estimated earnings for the next quarter are −0.43 USD. See more details about OpGen, Inc. earnings.
OpGen, Inc. revenue for the last quarter amounts to 736.14 K USD despite the estimated figure of 900.00 K USD. In the next quarter revenue is expected to reach 900.00 K USD.
Yes, you can track OpGen, Inc. financials in yearly and quarterly reports right on TradingView.
OPGN stock has fallen by 13.23% compared to the previous week, the month change is a 28.51% rise, over the last year OpGen, Inc. has showed a 41.88% decrease.
OPGN net income for the last quarter is −4.06 M USD, while the quarter before that showed −5.83 M USD of net income which accounts for 30.28% change. Track more OpGen, Inc. financial stats to get the full picture.
Today OpGen, Inc. has the market capitalization of 6.01 M, it has increased by 25.60% over the last week.
No, OPGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, OPGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OpGen, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 100.00 employees. See our rating of the largest employees — is OpGen, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OpGen, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OpGen, Inc. stock shows the sell signal. See more of OpGen, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OpGen, Inc. EBITDA is −16.95 M USD, and current EBITDA margin is −789.17%. See more stats in OpGen, Inc. financial statements.